Marinos C. Dalakas, MD
Professor
Division Chief, Neuromuscular Medicine
Contact
901 Walnut Street
Suite 400
Philadelphia, PA 19107
215-955-7952
215-955-9976 fax
Marinos C. Dalakas, MD
Professor
Division Chief, Neuromuscular Medicine
Education
Medical School
National University of Athens Medical School, Athens Greece
Residency
UMDNJ - NJ University of Medicine and Dentistry
Fellowship
Neuromuscular Medicine, NINCDS
Publications
- N2 Year in Review
- Reader Response: Intravenous Immunoglobulin Therapy in Patients with Painful Idiopathic Small-Fiber Neuropathy
- Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody-Positive Stiff-Person Syndrome
- Comment: Humoral and T-cell Immunities to SARS-CoV-2 Vaccines: Safety, Efficacy, and Challenges in Autoimmune Neurology
- Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values
- Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID
- Therapeutic Antibodies in Neurological Diseases: Witnessing the Continuation of the Impressive Success in Neuro-Immunotherapies
- The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies
- Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): mechanisms of action and clinical and genetic considerations
- The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders
- Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis
- Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis
- Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits
- Limited Benefits Halt Enrollment in Hematopoietic Stem Cell Transplantation Trial for Stiff-Person Syndrome: Should There Be More to Come?
- Treatment and Management of Autoimmune Myopathies
- N2 year in review
- N2 year in review
- The immunobiology of autoimmune encephalitides
- Case 22-2019: A 65-year-old woman with myopathy
- Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis
Board Certification
American Board of Psychiatry and Neurology
Hospital Appointment
Thomas Jefferson University Hospital
Research & Clinical Interests
Dr Dalakas’ areas of clinical and research interests are broad but mostly focused on neuroimmunology, neurovirology, genetics, and immunotherapies in neurologic diseases with application and design of new therapies. Among the diseases